Pyxis Oncology Launches Public Offering to Fund Phase 3 MICVO Trial
PYXS has more than doubled off its 52-week low of $1.03 on light trading volume (0.2× avg).
Summary
Pyxis Oncology has commenced a registered public offering of common stock (or pre-funded warrants) with accompanying common warrants. The warrants become exercisable only after stockholder approval to increase authorized shares, and expire on the earlier of five years from effectiveness or 30 days after OS data release from the Phase 1 MICVO study, expected in H1 2027. Proceeds will fund the planned Phase 3 Headliner trial in 2L+ R/M HNSCC and working capital. This follows the $50M private placement in July and the recent Phase 1 data showing 36% cORR. The offering is dilutive and comes amid a going concern warning; terms are not yet set, but the structure suggests a need for capital ahead of the pivotal trial. The stock tumbled following the announcement.
Updates
· SEC 424B5 — The preliminary prospectus sets the offering terms: common stock or pre-funded warrants with common warrants, exercise price $0.001 for pre-funded warrants, common warrant exercise price to be determined, and stockholder meeting within 60 days after closing to approve charter amendment.
At the time of this announcement, PYXS was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.9M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.